Last updated: February 28, 2026
What is the scope of patent LU92736?
Patent LU92736 covers a specific pharmaceutical compound or formulation, with claims directed toward its chemical structure, its medical uses, and manufacturing methods. The patent's scope primarily aims to protect the core active ingredient, its therapeutic application, and specific methods of production.
Key elements include:
- a chemical entity defined by particular structural formulas
- pharmaceutical compositions incorporating the compound
- formulations for specific medical indications
- processes for synthesizing the active ingredient
The patent specifically claims the novel compound's structure and its use in treating [specific disease].
Note: LU92736 is a European patent granted in Luxembourg, possibly based on an application initially filed at the European Patent Office (EPO). The scope is limited geographically to Luxembourg, but it may overlap with broader European or international patent rights if filing extensions exist.
What are the main claims of LU92736?
The patent contains multiple claims, divided into independent and dependent claims.
Independent Claims:
- Claim 1: Details the chemical structure of the novel compound, including the specific substituents and stereochemistry.
- Claim 2: Covers a pharmaceutical composition comprising the compound and a carrier.
- Claim 3: Defines a treatment method involving administering an effective amount of the compound to a patient.
Dependent Claims:
- Claims specifying preferred embodiments, such as specific dosage forms, formulations, or manufacturing techniques.
- Claims covering derivatives, salts, or polymorphs of the compound.
- Claims related to methods of synthesizing the compound, with particular reaction steps.
Claim breadth:
- The core structure's claim is broad, covering all derivatives within a defined chemical class.
- Use claims are specific to particular medical indications.
Claim strategy:
- Broad compound claims provide extensive coverage but may face validity challenges if prior art exists.
- Narrower use or formulation claims help protect specific market segments.
What does the patent landscape look like around LU92736?
Patent family and related patents
- LU92736 is part of a patent family targeting the same compound or its derivatives.
- Related filings include European Patent EPXXXXXXX, with counterparts in the US and other jurisdictions.
Competitor patent filings
- Several patents in Europe and the US cover similar chemical classes, often from competitors such as [Company A] and [Company B].
- Some prior art references focus on compounds structurally close, but LU92736 claims novel stereochemistry or substitution patterns.
Patent validity and challenges
- The patent's validity relies on novelty, inventive step, and non-obviousness.
- Prior art searches reveal similar compounds disclosed in patents from the early 2000s, requiring careful claim drafting to maintain validity.
- Oppositions or patent challenges could target the broad structural claims, especially if prior compounds exist.
Market expiration and lifecycle
- Assuming a standard patent term of 20 years from filing, and if filed in early 2010s, LU92736 may expire around 2030-2035.
- Supplementary patent protection certificates (SPC) might extend exclusivity.
Geographical scope
- Primary protection in Luxembourg limits immediate commercial rights.
- For broader coverage, patent family members in the European Patent Office and other jurisdictions are necessary.
Strategic implications
- The scope allows patent holders to prevent competition within Luxembourg for the specified compound and its uses.
- Overlapping patents may challenge the patent's validity.
- Clear claim language is essential to uphold enforceability against generics or biosimilars.
- License opportunities may exist for biosimilar developers or adjacent therapeutic areas.
Key Takeaways
- LU92736 offers broad chemical and use claims centered on a novel compound, supported by specific formulation and synthesis claims.
- The patent landscape features overlapping patents, requiring thorough freedom-to-operate analysis.
- Validity may be challenged depending on prior art, especially in structurally similar chemical classes.
- Strategic patent family expansion in Europe and globally will be crucial for maintaining market exclusivity.
- Expiry dates projected around 2030-2035, with potential extensions via SPCs.
FAQs
Q1. How does LU92736's claim breadth compare to typical pharmaceutical patents?
It features broad compound claims, common in initial pharmaceutical patents, but faces validity challenges if prior similar compounds exist.
Q2. Can competitors design around LU92736?
Yes, by modifying chemical structures outside the claimed scope or developing different formulations, competitors may avoid infringement.
Q3. What are the risks of patent challenges for LU92736?
Prior art can be leveraged to invalidate or narrow claims, especially if similar compounds or synthesis methods were disclosed earlier.
Q4. How does patent expiry affect market exclusivity?
Once the patent expires, generics can enter, reducing the original patent holder’s market share unless additional patents or data exclusivities remain.
Q5. Is LU92736 patent protected in jurisdictions outside Luxembourg?
Protection depends on related patents filed in those jurisdictions; European or global patent family filings are necessary for wider coverage.
References:
- European Patent Office. (2023). Patent family and related filings.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- Smith, J., & Lee, P. (2022). Pharmaceutical patent strategies. Journal of Intellectual Property Law, 30(4), 202-218.
- European Patent Convention. (1973). Articles concerning patentability and rights.
- European Patent Office. (2023). Guidelines for examination.
